Zacks Investment Research downgraded shares of Recro Pharma (NASDAQ:REPH) from a buy rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports.
According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
Several other equities analysts also recently issued reports on REPH. ValuEngine upgraded Recro Pharma from a hold rating to a buy rating in a research report on Friday, May 24th. Oppenheimer lifted their price objective on Recro Pharma from $9.00 to $15.00 and gave the company an outperform rating in a research report on Thursday, April 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Recro Pharma has a consensus rating of Buy and an average target price of $11.30.
REPH traded down $0.04 during trading on Friday, hitting $9.39. The company’s stock had a trading volume of 10,544 shares, compared to its average volume of 151,772. The company’s 50 day moving average price is $9.93. Recro Pharma has a 12 month low of $5.30 and a 12 month high of $10.69. The company has a market capitalization of $209.17 million, a PE ratio of -3.71 and a beta of -0.27.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.69. Recro Pharma had a negative return on equity of 472.52% and a negative net margin of 83.56%. The firm had revenue of $25.07 million during the quarter, compared to the consensus estimate of $20.51 million. As a group, sell-side analysts anticipate that Recro Pharma will post -0.54 EPS for the current year.
In related news, Director Arnaud Ajdler acquired 40,000 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was acquired at an average cost of $9.00 per share, with a total value of $360,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Geraldine Henwood sold 144,806 shares of Recro Pharma stock in a transaction on Monday, May 13th. The stock was sold at an average price of $8.89, for a total value of $1,287,325.34. Following the sale, the chief executive officer now directly owns 342,947 shares of the company’s stock, valued at $3,048,798.83. The disclosure for this sale can be found here. 20.10% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in REPH. Wedge Capital Management L L P NC acquired a new stake in shares of Recro Pharma during the second quarter worth $1,682,000. Cadence Capital Management LLC acquired a new stake in shares of Recro Pharma during the first quarter worth $803,000. Kennedy Capital Management Inc. grew its stake in shares of Recro Pharma by 19.5% during the first quarter. Kennedy Capital Management Inc. now owns 598,107 shares of the specialty pharmaceutical company’s stock worth $3,505,000 after purchasing an additional 97,482 shares during the period. BlackRock Inc. grew its stake in shares of Recro Pharma by 5.7% during the fourth quarter. BlackRock Inc. now owns 1,154,815 shares of the specialty pharmaceutical company’s stock worth $8,199,000 after purchasing an additional 62,787 shares during the period. Finally, Chicago Equity Partners LLC acquired a new stake in shares of Recro Pharma during the second quarter worth $576,000. 57.18% of the stock is owned by institutional investors and hedge funds.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Article: Diversification
Get a free copy of the Zacks research report on Recro Pharma (REPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.